MEP20408A - Pharmaceutical dronedarone composition for parenteral administration - Google Patents
Pharmaceutical dronedarone composition for parenteral administrationInfo
- Publication number
- MEP20408A MEP20408A MEP-204/08A MEP20408A MEP20408A ME P20408 A MEP20408 A ME P20408A ME P20408 A MEP20408 A ME P20408A ME P20408 A MEP20408 A ME P20408A
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutical
- parenteral administration
- dronedarone
- composition
- dronedarone composition
- Prior art date
Links
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002084 dronedarone Drugs 0.000 title abstract 2
- 238000007911 parenteral administration Methods 0.000 title 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0016071A FR2817750B1 (fr) | 2000-12-11 | 2000-12-11 | Composition pharmaceutique de dronedarone pour administration parenterale |
| PCT/FR2001/003903 WO2002047660A1 (fr) | 2000-12-11 | 2001-12-10 | Composition pharmaceutique de dronedarone pour administration parenterale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP20408A true MEP20408A (en) | 2010-06-10 |
Family
ID=8857483
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-204/08A MEP20408A (en) | 2000-12-11 | 2001-12-10 | Pharmaceutical dronedarone composition for parenteral administration |
| MEP-2008-204A ME00083B (me) | 2000-12-11 | 2001-12-10 | Farmaceutski oblik dronedarona za parenteralnu upotrebu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-204A ME00083B (me) | 2000-12-11 | 2001-12-10 | Farmaceutski oblik dronedarona za parenteralnu upotrebu |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6939865B2 (cs) |
| EP (1) | EP1343473B1 (cs) |
| JP (1) | JP4399161B2 (cs) |
| KR (1) | KR100849758B1 (cs) |
| CN (1) | CN1235566C (cs) |
| AR (1) | AR031649A1 (cs) |
| AT (1) | ATE348599T1 (cs) |
| AU (2) | AU2002217229B2 (cs) |
| BG (1) | BG66187B1 (cs) |
| BR (1) | BR0116060B1 (cs) |
| CA (1) | CA2427375C (cs) |
| CZ (1) | CZ297788B6 (cs) |
| DE (1) | DE60125411T2 (cs) |
| EA (1) | EA005314B1 (cs) |
| FR (1) | FR2817750B1 (cs) |
| HU (1) | HU229372B1 (cs) |
| IL (2) | IL155428A0 (cs) |
| IS (1) | IS2349B (cs) |
| MA (1) | MA26969A1 (cs) |
| ME (2) | MEP20408A (cs) |
| MX (1) | MXPA03005221A (cs) |
| NO (1) | NO332294B1 (cs) |
| NZ (1) | NZ525661A (cs) |
| OA (1) | OA12416A (cs) |
| PL (1) | PL199846B1 (cs) |
| RS (1) | RS50348B (cs) |
| SK (1) | SK287115B6 (cs) |
| TW (1) | TWI246926B (cs) |
| WO (1) | WO2002047660A1 (cs) |
| ZA (1) | ZA200303406B (cs) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009526851A (ja) * | 2006-02-14 | 2009-07-23 | ワイス | ＥＲβ選択的リガンドの水性薬学的配合物 |
| GB0719180D0 (en) | 2007-10-02 | 2007-11-14 | Cambrex Karlskoga Ab | New process |
| FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
| WO2009144550A2 (en) | 2008-04-17 | 2009-12-03 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
| EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
| FR2959132A1 (fr) * | 2010-04-22 | 2011-10-28 | Sanofi Aventis | Procedes pour l'evaluation et la reduction des risques |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| US20120005128A1 (en) * | 2010-06-29 | 2012-01-05 | Sanofi | Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation |
| US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
| CN102342907A (zh) | 2010-07-30 | 2012-02-08 | 江苏恒瑞医药股份有限公司 | 决奈达隆固体分散体及其制备方法 |
| KR20120094557A (ko) * | 2011-02-01 | 2012-08-27 | 동아제약주식회사 | 피에이치 비의존적 용출양상을 갖는 부정맥치료제 제제 |
| CN102908307A (zh) * | 2011-08-03 | 2013-02-06 | 天津市嵩锐医药科技有限公司 | 供注射用盐酸决奈达隆药物组合物及其制备方法 |
| CN104470500A (zh) * | 2012-07-12 | 2015-03-25 | 赛诺菲 | 包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物 |
| CN114377148B (zh) * | 2020-10-20 | 2023-09-29 | 上海博志研新药物研究有限公司 | 盐酸决奈达隆药物组合物、其制备方法及应用 |
| WO2023019993A1 (zh) * | 2021-08-16 | 2023-02-23 | 上海博志研新药物技术有限公司 | 盐酸决奈达隆注射组合物、其制备方法及应用 |
| EP4527375A1 (en) * | 2022-12-07 | 2025-03-26 | RemeGen Co., Ltd. | Taci-fc fusion protein liquid pharmaceutical preparation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
| JP2004327321A (ja) * | 2003-04-25 | 2004-11-18 | Jst Mfg Co Ltd | コネクタ |
-
2000
- 2000-12-11 FR FR0016071A patent/FR2817750B1/fr not_active Expired - Fee Related
-
2001
- 2001-12-10 AU AU2002217229A patent/AU2002217229B2/en not_active Ceased
- 2001-12-10 JP JP2002549234A patent/JP4399161B2/ja not_active Expired - Fee Related
- 2001-12-10 HU HU0500842A patent/HU229372B1/hu not_active IP Right Cessation
- 2001-12-10 DE DE60125411T patent/DE60125411T2/de not_active Expired - Lifetime
- 2001-12-10 ZA ZA200303406A patent/ZA200303406B/en unknown
- 2001-12-10 AU AU1722902A patent/AU1722902A/xx active Pending
- 2001-12-10 CZ CZ20031612A patent/CZ297788B6/cs not_active IP Right Cessation
- 2001-12-10 CN CNB018203884A patent/CN1235566C/zh not_active Expired - Fee Related
- 2001-12-10 TW TW090130522A patent/TWI246926B/zh not_active IP Right Cessation
- 2001-12-10 ME MEP-204/08A patent/MEP20408A/xx unknown
- 2001-12-10 ME MEP-2008-204A patent/ME00083B/me unknown
- 2001-12-10 BR BRPI0116060-5B1A patent/BR0116060B1/pt not_active IP Right Cessation
- 2001-12-10 RS YUP-465/03A patent/RS50348B/sr unknown
- 2001-12-10 MX MXPA03005221A patent/MXPA03005221A/es active IP Right Grant
- 2001-12-10 CA CA2427375A patent/CA2427375C/fr not_active Expired - Fee Related
- 2001-12-10 WO PCT/FR2001/003903 patent/WO2002047660A1/fr not_active Ceased
- 2001-12-10 NZ NZ525661A patent/NZ525661A/en not_active IP Right Cessation
- 2001-12-10 PL PL362788A patent/PL199846B1/pl unknown
- 2001-12-10 AR ARP010105716A patent/AR031649A1/es not_active Application Discontinuation
- 2001-12-10 US US10/450,320 patent/US6939865B2/en not_active Expired - Lifetime
- 2001-12-10 OA OA1200300152A patent/OA12416A/fr unknown
- 2001-12-10 AT AT01270322T patent/ATE348599T1/de not_active IP Right Cessation
- 2001-12-10 SK SK726-2003A patent/SK287115B6/sk not_active IP Right Cessation
- 2001-12-10 EA EA200300406A patent/EA005314B1/ru not_active IP Right Cessation
- 2001-12-10 KR KR1020037007744A patent/KR100849758B1/ko not_active Expired - Fee Related
- 2001-12-10 IL IL15542801A patent/IL155428A0/xx active IP Right Grant
- 2001-12-10 EP EP01270322A patent/EP1343473B1/fr not_active Expired - Lifetime
-
2003
- 2003-04-14 IL IL155428A patent/IL155428A/en not_active IP Right Cessation
- 2003-04-18 BG BG107748A patent/BG66187B1/bg unknown
- 2003-04-29 NO NO20031958A patent/NO332294B1/no not_active IP Right Cessation
- 2003-04-30 IS IS6801A patent/IS2349B/is unknown
- 2003-06-03 MA MA27190A patent/MA26969A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP20408A (en) | Pharmaceutical dronedarone composition for parenteral administration | |
| HRP20020880B1 (en) | New pharmaceutical composition | |
| EE05081B1 (et) | Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid | |
| MEP33708A (hr) | Farmaceutske smješe koje obuhvataju inhibitor hmg coa reduktaze | |
| NO20025621D0 (no) | Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser | |
| CY1110906T1 (el) | Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης | |
| MEP39108A (en) | Pharmaceutical composition | |
| EP1100522A4 (en) | ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG | |
| EP1246622A4 (en) | NEW SUBSTITUTED DOSE FORMS OF BENZIMIDAZOLENES AND METHOD FOR THE USE THEREOF | |
| HRP20020198B1 (hr) | Formulacija moksifloksacina i kuhinjske soli | |
| FR2805818B1 (fr) | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant | |
| DK1766003T3 (da) | Thrombinpræparater | |
| MY122124A (en) | Solid pharmaceutical composition containing benzofurane derivatives | |
| HRP20010243B1 (hr) | Pripravci koji sadrže difosfonske kiseline | |
| CY1112139T1 (el) | Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης | |
| BG102857A (en) | Antimycotic substance-containing and acetate buffer-containing compositions | |
| ATE198834T1 (de) | Konjugate bestehend aus polysaccharid und protein | |
| DK1104289T3 (da) | Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister | |
| CY1107819T1 (el) | Φαρμακευτικη διαμορφωση της ολανζαπινης | |
| MXPA01011842A (es) | Composiciones farmaceuticas para la administracion oral de floroglucinol y preparacion de las mismas. | |
| MXPA03004111A (es) | Composiciones de n-(1 -metiletilaminocarbonil)-4 -(3-metilfenilamino) -3-piridil-sulfonamida y oligosacaridos ciclicos con una mayor liberacion. | |
| CL2011000439A1 (es) | Formulacion farmaceutica que consiste esencialmente de 50 mg/ml de clorhidrato de canfosfamida en 100 mm de un amortiguador acuoso de citrato de sodio a ph 4,6; formulacion liofilizada que la comprende; y metodo de preparacion de la formulacion farmaceutica. | |
| ES2197781A1 (es) | Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno. | |
| YU87501A (sh) | Farmaceutski kompleksi | |
| MEP18508A (en) | Pharmaceutical composition and preparation thereof |